Barbara Gayle Duncan, Chief Financial Officer at INTERCEPT PHARMACEUTICALS INC (ICPT), sold 28,100 shares at $34.50 ($969K) on 2013-05-20, disclosed to the SEC on 2013-05-22.
Scheduled sale ($969k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $34.50 | 100 | $3K | 0.4% |
| 2 | $34.50 | 28,000 | $966K | 99.6% |
| Total | $34.50 avg | 28,100 | $969K | 100% |
| Filing → |
| JNCE | SELL | 2018-01-29 | $100K | — | Filing → |
| GNMX | BUY | 2017-10-18 | $150K | — | Filing → |
| ICPT | SELL | 2016-10-05 | $24K | — | Filing → |